Abbott Laboratories $ABT Shares Acquired by Madison Asset Management LLC

Madison Asset Management LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 16.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 97,681 shares of the healthcare product maker’s stock after purchasing an additional 13,848 shares during the period. Madison Asset Management LLC’s holdings in Abbott Laboratories were worth $12,238,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ABT. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth about $27,000. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories in the 3rd quarter valued at about $31,000. Bridge Generations Wealth Management LLC acquired a new position in Abbott Laboratories in the 3rd quarter valued at about $33,000. Finally, Copia Wealth Management acquired a new position in Abbott Laboratories in the 3rd quarter valued at about $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT stock opened at $83.83 on Thursday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock’s 50 day moving average price is $100.17 and its 200 day moving average price is $113.85. The firm has a market cap of $146.02 billion, a P/E ratio of 23.48, a PEG ratio of 1.41 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Recent insider-buying coverage highlighted Abbott alongside other companies with insider purchases, which can be interpreted as a sign of confidence from management or executives. Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell (ABT)
• Positive Sentiment: Wall Street sentiment remains relatively constructive, with articles noting that analysts are still broadly optimistic on Abbott and that the stock’s dividend yield has risen to a decade-high level, which may attract value-oriented investors. Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Abbott is also being highlighted in broader healthcare and regenerative-medicine market research, reinforcing that it remains a major player in long-term growth markets, though this is not an immediate stock catalyst. Australia Regenerative Medicine Market Research Trends and Forecasts Report 2026-2035 Featuring Prominent Players Such as Abbott Laboratories, Astellas Pharma, and Roche
• Negative Sentiment: Investors remain focused on Abbott’s post-earnings weakness, including concerns about Exact Sciences dilution, legal risks, and soft diagnostics trends, which have weighed on sentiment and helped keep shares depressed. Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?
• Negative Sentiment: Older commentary also pointed to Abbott trading at a low valuation after the Exact Sciences deal and legal judgments, suggesting the market is still discounting uncertainty around earnings quality and integration costs. Abbott’s dividend yield near decade peak, signaling rare buying opportunity

Insiders Place Their Bets

In related news, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ABT. Wells Fargo & Company dropped their price target on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research report on Wednesday, April 22nd. UBS Group dropped their price target on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Weiss Ratings cut Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, April 24th. Finally, Evercore lowered their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.